Flash Finance

Amrutanjan Health Care LimitedAMRUTANJANCorporate

Pharmaceuticals - Indian - Formulations Latest results: Jun 2026 14 quarters of data
Consolidated Standalone
₹513.80
MCap ₹1,485 Cr · P/E 27.6
Amrutanjan Health Care Limited — Stock analysis & AI research Amrutanjan Health Care Limited — Multibagger AI analysis Amrutanjan Health Care Limited — Seasonality — best & worst months Amrutanjan Health Care Limited — Technical setup — score, trend, support & resistance Amrutanjan Health Care Limited — Live exchange announcements
📈 MACD Bullish Crossover📈 Bollinger Squeeze Stocks📈 Stocks Above Anchored VWAP 🏭 Pharma sector
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹103 Cr
Sales · Jun 2026
+9.5% YoY
₹6 Cr
Operating Profit · Jun 2026
-22.0% YoY
6.1%
OPM % · Jun 2026
-28.2% YoY
₹4 Cr
Net Profit · Jun 2026
-45.4% YoY
₹1.51
EPS · Jun 2026
-47.4% YoY

📝 Amrutanjan Health Care Limited — results explained

Quarter ended June 2026 (Q1 FY27)

Amrutanjan Health Care Limited reported revenue of ₹103 crore for the quarter ended June 2026 (Q1 FY27), up 9.5% from ₹94 crore in the same quarter last year, and down 31.4% sequentially over the March 2026 quarter.

Net profit fell 45.4% year-on-year to ₹4 crore, from ₹8 crore. Earnings per share (EPS) came in at ₹1.51.

Operating profit stood at ₹6 crore — an operating margin (OPM) of 6.1%, compared with 8.5% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Amrutanjan Health Care Limited posted revenue of ₹503 crore, a growth of 11.0% over FY25, with a net profit of ₹57 crore (up 1.3% year-on-year).

On a trailing-twelve-month (TTM) basis, revenue stands at ₹512 crore with a net profit of ₹54 crore.

Valuation snapshot

At the current price of ₹513.80, AMRUTANJAN has a market capitalisation of ₹1,485 crore and a trailing P/E of about 27.6.

Within the Pharmaceuticals - Indian - Formulations industry, it is the 10th-largest of the 20 companies we track by market value.

Shareholding pattern

As of Sep 2026, promoters held 46.52%, foreign institutional investors (FIIs) 3.47%, domestic institutional investors (DIIs) 6.90%, public shareholders 43.08% of Amrutanjan Health Care Limited.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹1,485 Cr
Current Price ?
₹513.8
P/E ?
27.61above ind
Industry P/E ?
21.30
P/B ?
4.01
P/S ?
2.90
P/FCF ?
-78.15
Enterprise Value ?
₹1,487 Cr
EV/EBITDA ?
20.11
PEG ?
1.62
Earnings Yield ?
4.5%
Dividend Yield ?
0.90%
Profitability & Returns
Sales (TTM) ?
₹512 Cr
OPM ?
14.4%
Profit after tax (TTM) ?
₹54 Cr
EPS (TTM) ?
₹18.61
ROCE ?
25.0%
ROE ?
14.5%
ROA ?
10.6%
Growth
Sales — latest qtr ?
₹103 Cr
PAT — latest qtr ?
₹4 Cr
YoY qtr sales growth ?
9.5%
YoY qtr profit growth ?
-45.4%
Sales growth (3y) ?
10%
Sales growth (5y) ?
9%
Profit growth (3y) ?
17%
Profit growth (5y) ?
1%
Financial Health
Debt ?
₹2 Cr
Debt to Equity ?
0.01
Interest Coverage ?
702.0
Current Ratio ?
N/A
Ownership
Promoter holding ?
46.52%
Change in promoter holding ?
0.00%
Pledged percentage ?
N/A
Market
Return 3 months ?
-4.5%
Return 6 months ?
-6.1%

🗓️ Quarterly results (14 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best
Metric Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026 YoY % QoQ %
Sales 100781021171278411112313594118141150103 +9.5% -31.4%
Operating Profit 137232216421231881725266 -22.0% -76.0%
Other Income 543454545444-34 -4.6% +227.2%
Interest 00000000000000 — —
Depreciation 11222222222222 -4.2% -4.2%
Profit Before Tax 1692424206242621111926216 -44.8% -71.1%
Net Profit 137181714518191581419164 -45.4% -72.7%
EPS 4.342.406.306.054.721.606.116.665.252.874.836.735.601.51 -47.4% -73.0%
OPM % 13.0% 9.2% 22.5% 18.4% 12.8% 4.2% 18.7% 19.0% 13.1% 8.5% 14.0% 17.8% 17.3% 6.1% -28.2% -64.7%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric FY25 FY26 TTM YoY %
Sales ₹453 Cr ₹503 Cr ₹512 Cr +11.0%
Operating Profit ₹65 Cr ₹76 Cr ₹74 Cr +16.0%
OPM % 14.42% 15.06% 14.45% +4.4%
NPM % 12.52% 11.42% 10.51% -8.8%
Other Income ₹19 Cr ₹9 Cr ₹9 Cr -50.6%
Depreciation ₹7 Cr ₹7 Cr ₹7 Cr +7.1%
Interest ₹1 Cr ₹0 Cr ₹0 Cr -81.0%
EBIT ₹59 Cr ₹69 Cr ₹67 Cr +17.0%
PBT ₹77 Cr ₹78 Cr ₹73 Cr +0.6%
Tax ₹15 Cr ₹7 Cr ₹9 Cr -53.1%
Net Profit ₹57 Cr ₹57 Cr ₹54 Cr +1.3%
EPS ₹19.62 ₹20.03 ₹18.67 +2.1%
Material Cost ₹212 Cr ₹122 Cr ₹184 Cr -42.2%
Employee Cost ₹62 Cr ₹32 Cr ₹50 Cr -48.4%
Extraordinary Items — ₹-1 Cr ₹-3 Cr —

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Equity Capital 3333 +0.0%
Reserves 288286324367 +13.3%
Borrowings 1222 +0.0%
Other Liabilities 707793137 +47.3%
Total Liabilities 362367421509 +20.9%
Fixed Assets 49504951 +4.1%
CWIP 1216105 +556.2%
Investments 5003 —
Other Assets 307315356349 -2.0%
Total Assets 362367421509 +20.9%

💧 Cash Flow (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Cash from Operating Activity 20285136 -29.4%
Cash from Investing Activity -219-31-21 +32.3%
Cash from Financing Activity -15-48-13-14 -7.7%
Net Cash Flow 3-161 -83.3%
Free Cash Flow 112115-19 -226.7%
CFO/OP 81%86%118%73% -38.1%

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Debtor Days 32424544 -2.2%
Inventory Days 58504556 +24.4%
Days Payable 9596113106 -6.2%
Cash Conversion Cycle -6-5-23-6 +73.9%
Working Capital Days 1171739996 -3.0%
ROCE % 19%21%22%25% +13.6%

👥 Shareholding (latest 5 periods)

Metric Jun 2025Sep 2025Dec 2025Mar 2026Sep 2026 % Chg
Promoters 46.52%46.52%46.52%46.52%46.52% +0.0%
FIIs 2.41%2.38%2.27%2.17%3.47% +59.9%
DIIs 12.70%12.90%13.00%12.66%6.90% -45.5%
Public 38.34%38.16%38.18%38.61%43.08% +11.6%
Others 0.04%0.04%0.04%0.04%— —
No. of Shareholders 49,43147,95446,67545,80546,186 +0.8%

⚖️ Peer comparison

Industry: Pharmaceuticals - Indian - Formulations · 20 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 SHILPAMED Shilpa Medicare ₹1,032.00 20,184 67.5 1,683 297 28.4% 17.7% 47.7% 454.9% 44.9% 115.2%
2 MARKSANS Marksans Pharma ₹332.50 15,068 29.1 3,171 521 22.5% 16.4% 12.5% 9.7% 35.6% 174.8%
3 BLISSGVS Bliss GVS ₹680.50 7,236 52.9 1,005 142 19.7% 14.1% 14.4% 48.7% 37.6% 15.8%
4 JSLL Jeena Sikho ₹507.55 6,309 26.7 852 236 42.6% 27.7% 17.1% 85.5% 28.8% 28.0%
5 SENORES Senores Pharmaceuticals ₹1,327.50 6,114 46.6 692 131 29.5% 19.0% 63.0% 108.7% 30.6% 43.8%
6 WINDLAS Windlas Biotech ₹1,129.50 2,331 35.7 942 66 11.1% 7.1% 18.9% 9.0% 18.1% -0.1%
7 VENUSREM Venus Remedies ₹1,651.10 2,210 19.0 811 117 20.4% 14.4% 17.9% 127.9% 35.6% 139.3%
8 SYNCOMF Syncom Formulations ₹23.44 2,203 1.3 12,547 1,729 15.2% 13.8% 2566.9% 3386.8% 7.4% 57.7%
9 HESTERBIO Hester Biosciences ₹2,187.90 1,861 13.6 318 137 30.8% 43.0% 4.7% 101.2% -8.4% 460.8%
10 AMRUTANJAN Amrutanjan Health ₹489.00 1,413 26.2 512 54 14.4% 10.5% 11.0% 1.3% 9.5% -45.4%
11 LINCOLN Lincoln Pharmaceuticals ₹601.50 1,205 12.5 694 97 14.6% 14.0% 7.6% 7.2% 15.1% 30.9%
12 BAFNAPH Bafna Pharmaceuticals ₹301.45 713 91.6 143 8 8.2% 5.5% 3.3% 166.8% -23.2% -97.8%
13 KILITCH Kilitch Drugs ₹198.00 692 16.1 237 29 15.3% 12.3% 18.7% 20.1% 4.0% -13.0%
14 MEDICAMEQ Medicamen Biotech ₹323.80 439 1.3 9,516 381 10.1% 4.0% 5751.8% 3308.0% 11.3% 15.3%
15 QUESTLAB Quest Laboratories ₹137.50 225 13.7 150 16 12.7% 11.0% 25.8% 34.9% -30.2% 47.9%
16 JFLLIFE Jfl Life ₹51.05 168 24.7 131 7 9.1% 5.2% 60.2% 53.1% -4.2% 48.5%
17 ZENITHDRUG Zenith ₹78.45 135 41.7 171 4 7.0% 2.3% — — 40.9% 100.0%
18 ALPA Alpa Laboratories ₹62.32 131 29.6 111 4 1.7% 4.0% -5.9% -22.5% 25.2% -91.7%
19 MEDIORG Medicamen ₹101.45 119 — 22 -3 -12.9% -14.0% — — -77.5% -383.0%
20 BIOFILCHEM Biofil Chemicals ₹33.13 54 110.4 34 0 2.3% 1.4% -15.0% 405.5% 92.1% -95.5%
❓ Frequently asked questions
What was Amrutanjan Health Care Limited's revenue in Q1 FY27?
Amrutanjan Health Care Limited reported revenue of ₹103 crore for the quarter ended June 2026 (Q1 FY27), up 9.5% from ₹94 crore in the same quarter last year, and down 31.4% sequentially over the March 2026 quarter.
What was Amrutanjan Health Care Limited's net profit in Q1 FY27?
Net profit fell 45.4% year-on-year to ₹4 crore, from ₹8 crore. Earnings per share (EPS) came in at ₹1.51.
What is AMRUTANJAN's market capitalisation and P/E ratio?
At the current price of ₹513.80, AMRUTANJAN has a market capitalisation of ₹1,485 crore and a trailing P/E of about 27.6.
Who owns Amrutanjan Health Care Limited? (shareholding pattern)
As of Sep 2026, promoters held 46.52%, foreign institutional investors (FIIs) 3.47%, domestic institutional investors (DIIs) 6.90%, public shareholders 43.08% of Amrutanjan Health Care Limited.
TTM ends 2026-06-30. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI